ArticleGHM open2024
Pain relief effect of metoclopramide
Article in GHM open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Saudi clinical practice guidelines for the treatment and prevention of migraine headache.Neurosciences (Riyadh, Saudi Arabia) · 2025Guideline
- Determinants of Unpaid Hospital Charges Among Non-Resident Foreign Patients: A Retrospective Single-Center Study in Tokyo, Japan.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triptans are recommended as a treatment for moderate to severe migraines; however, barriers to administration include contraindications or possible side effects. In contrast, metoclopramide, which is frequently used as an antiemetic in the emergency department setting, has shown efficacy in alleviating migraine pain. This study investigated the non-inferiority of intravenously (IV) administered metoclopramide 10 mg compared with subcutaneously (SQ) administered sumatriptan 3 mg for alleviating migraine pain. In this single-center, open-label, cluster-randomized controlled trial, patients presenting to the emergency department with migraine attacks were allocated to either the IV metoclopramide 10 mg group or the SQ sumatriptan 3 mg group. The primary outcome was change in numerical rating scale (NRS) score for headache at 1 h after baseline. The non-inferiority margin was set as -1.0 NRS points. Thirty-six patients were enrolled over a period of 3 years, starting from July 2019. Reduction in NRS at 1 h was 4.1 (95% confidence interval [CI]: 2.8, 5.4) in the metoclopramide group and 5.2 (95% CI: 4.2, 6.1) in the sumatriptan group, with a mean difference of -1.1 (95% CI: -2.7, 0.4), indicating that metoclopramide was not non-inferior to sumatriptan. Four patients required rescue medication: 3 (18%) in the metoclopramide group and 1 (7%) in the sumatriptan group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.